Literature DB >> 19880776

Mantle cell lymphoma.

Stefano A Pileri, Brunangelo Falini.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19880776      PMCID： PMC2770958          DOI： 10.3324/haematol.2009.013359

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  22 in total

1.  Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data.

Authors:  P M Banks; J Chan; M L Cleary; G Delsol; C De Wolf-Peeters; K Gatter; T M Grogan; N L Harris; P G Isaacson; E S Jaffe
Journal:  Am J Surg Pathol       Date:  1992-07       Impact factor: 6.394

2.  SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.

Authors:  Ana Mozos; Cristina Royo; Elena Hartmann; Daphne De Jong; Cristina Baró; Alexandra Valera; Kai Fu; Dennis D Weisenburger; Jan Delabie; Shih-Sung Chuang; Elaine S Jaffe; Carmen Ruiz-Marcellan; Sandeep Dave; Lisa Rimsza; Rita Braziel; Randy D Gascoyne; Francisco Solé; Armando López-Guillermo; Dolors Colomer; Louis M Staudt; Andreas Rosenwald; German Ott; Pedro Jares; Elias Campo
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

3.  Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network.

Authors:  Markus Tiemann; Carsten Schrader; Wolfram Klapper; Martin H Dreyling; Elias Campo; Andrew Norton; Francoise Berger; Philip Kluin; German Ott; Stephano Pileri; Ennio Pedrinis; Alfred C Feller; Hartmut Merz; Dirk Janssen; Martin L Hansmann; Han Krieken; Peter Möller; Harald Stein; Michael Unterhalt; Wolfgang Hiddemann; Reza Parwaresch
Journal:  Br J Haematol       Date:  2005-10       Impact factor: 6.998

4.  Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma.

Authors:  D D Weisenburger; H Kim; H Rappaport
Journal:  Cancer       Date:  1982-04-01       Impact factor: 6.860

5.  Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling.

Authors:  Kai Fu; Dennis D Weisenburger; Timothy C Greiner; Sandeep Dave; George Wright; Andreas Rosenwald; Michael Chiorazzi; Javeed Iqbal; Stefan Gesk; Reiner Siebert; Daphne De Jong; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; German Ott; Bhavana J Dave; Warren G Sanger; Lynette M Smith; Lisa Rimsza; Rita M Braziel; H Konrad Müller-Hermelink; Elias Campo; Randy D Gascoyne; Louis M Staudt; Wing C Chan
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

6.  Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature.

Authors:  Itziar Salaverria; Andreas Zettl; Sílvia Beà; Victor Moreno; Joan Valls; Elena Hartmann; German Ott; George Wright; Armando Lopez-Guillermo; Wing C Chan; Dennis D Weisenburger; Randy D Gascoyne; Thomas M Grogan; Jan Delabie; Elaine S Jaffe; Emili Montserrat; Hans-Konrad Muller-Hermelink; Louis M Staudt; Andreas Rosenwald; Elias Campo
Journal:  J Clin Oncol       Date:  2007-02-12       Impact factor: 44.544

7.  Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR.

Authors:  Leticia Quintanilla-Martinez; Julia Slotta-Huspenina; Ina Koch; Margit Klier; Eric D Hsi; Laurence de Leval; Wolfram Klapper; Stefan Gesk; Reiner Siebert; Falko Fend
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

8.  Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse.

Authors:  S H Swerdlow; J A Habeshaw; L J Murray; H S Dhaliwal; T A Lister; A G Stansfeld
Journal:  Am J Pathol       Date:  1983-11       Impact factor: 4.307

Review 9.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

10.  Neoplastic and reactive follicles within B-cell malignant lymphomas. A morphological and immunological study of 30 cases.

Authors:  S Pileri; M T Rivano; M Gobbi; D Taruscio; K Lennert
Journal:  Hematol Oncol       Date:  1985 Oct-Dec       Impact factor: 5.271
View more
  27 in total

1.  Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.

Authors:  Hyun Joo Jung; Zheng Chen; Michael Wang; Luis Fayad; Jorge Romaguera; Larry W Kwak; Nami McCarty
Journal:  Blood       Date:  2012-01-31       Impact factor: 22.113

2.  Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component.

Authors:  Carlo Visco; Sylvia Hoeller; Jeffrey T Malik; Zijun Y Xu-Monette; Michele L Wiggins; Jessica Liu; Warren G Sanger; Zhongfeng Liu; Julie Chang; Erik A Ranheim; Joel F Gradowski; Sergio Serrano; Huan-You Wang; Qingquan Liu; Sandeep Dave; Brian Olsen; Randy D Gascoyne; Elias Campo; Steven H Swerdlow; Wing C Chan; Alexander Tzankov; Ken H Young
Journal:  Am J Surg Pathol       Date:  2011-02       Impact factor: 6.394

3.  A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

Authors:  Ryan D Cassaday; Andre Goy; Suresh Advani; Purvi Chawla; Rajesh Nachankar; Mansi Gandhi; Ajay K Gopal
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-03-05

4.  TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.

Authors:  Hua-Jie Dong; Li-Tao Zhou; Cheng Fang; Lei Fan; Dan-Xia Zhu; Yin-Hua Wang; Jian-Yong Li; Wei Xu
Journal:  Med Oncol       Date:  2011-11-06       Impact factor: 3.064

5.  Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy.

Authors:  Joanne E Davis; Sasanka M Handunnetti; Mandy Ludford-Menting; Chia Sharpe; Piers Blombery; Mary Ann Anderson; Andrew W Roberts; John F Seymour; Constantine S Tam; David S Ritchie; Rachel M Koldej
Journal:  Blood Adv       Date:  2020-10-13

6.  Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis.

Authors:  Sarah E Gibson; Steven H Swerdlow; Judith A Ferry; Urvashi Surti; Paola Dal Cin; Nancy Lee Harris; Robert P Hasserjian
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

7.  Anti-human CD99 antibody exerts potent antitumor effects in mantle cell lymphoma.

Authors:  Nuchjira Takheaw; Gunya Sittithumcharee; Ryusho Kariya; Watchara Kasinrerk; Seiji Okada
Journal:  Cancer Immunol Immunother       Date:  2020-11-19       Impact factor: 6.968

8.  A rare case of t(11;22) in a mantle cell lymphoma like B-cell neoplasia resulting in a fusion of IGL and CCND1: case report.

Authors:  Cristiano Krings Rocha; Inka Praulich; Iris Gehrke; Michael Hallek; Karl-Anton Kreuzer
Journal:  Mol Cytogenet       Date:  2011-04-01       Impact factor: 2.009

9.  Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.

Authors:  Hyun Joo Jung; Zheng Chen; Nami McCarty
Journal:  Am J Hematol       Date:  2012-09-11       Impact factor: 10.047

Review 10.  Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature.

Authors:  Reza Setoodeh; Stuart Schwartz; Peter Papenhausen; Ling Zhang; Elizabeth M Sagatys; Lynn C Moscinski; Haipeng Shao
Journal:  Int J Clin Exp Pathol       Date:  2013-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.